Osteoporosis News and Research

Latest Osteoporosis News and Research

Scientists attribute breast cancer decline to publicity surrounding WHI results

Between 2002 and 2003, American women experienced a 7 percent decline in breast cancer incidence, which scientists attribute to the publicity surrounding results of the Women's Health Initiative (WHI).

8 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

Patients new to chronic disease medication face risk of medication discontinuation, finds study

In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.

5 Dec 2009

Orthofix International announces the launch of its FUSION Lateral OA Brace

Orthofix International announced today that its sports medicine division, BREG, has expanded its successful line of FUSION® functional knee braces by introducing the FUSION® Lateral OA Brace, which features an ultra-thin low-profile hinge designed for individuals suffering from lateral compartment osteoarthritis (OA).

4 Dec 2009

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Osseon Therapeutics announced today that its Osseoflex (steerable and curvable bone cement delivery needle) and Osseoflex DR (steerable and curvable bone drill) systems for percutaneous vertebral augmentation received Canadian Medical Device Licenses from Health Canada for marketing and clinical use in Canada.

4 Dec 2009

Lung disease linked to the use of contaminated well water in a CPAP machine

Many people rely on continuous positive airway pressure (CPAP) machines as a safe and effective treatment for sleep apnea. But a new case report describes a rare complication—a lingering inflammatory disease of the lungs, apparently related to the use of contaminated well water in a CPAP machine. The report appears in the December Southern Medical Journal, official journal of the Southern Medical Association.

3 Dec 2009

New preventive screening packages for heart disease

HealthYes!®, a leading mobile medical screening provider, is offering several new preventive screenings directly focused on heart disease. The new tests include: a six-lead electrocardiogram (EKG), cholesterol finger-stick, and 10-year Framingham Cardiac Risk Score as well as diabetes and liver function testing.

2 Dec 2009

Anti-Aging Institute of California offers 'Don't Pause' to get rid of menopause symptoms

Menopause - it's an unavoidable part of aging as a woman, and brings with it a host of uncomfortable symptoms that negatively impact quality of life. Hot flashes, poor sleep, mood swings, weight gain, night sweats and lethargy are just some of the life-altering symptoms of menopause and perimenopause.

30 Nov 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Scientists offer first genetic proof of new and rational treatment for osteoporosis

The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309).

26 Nov 2009

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Flaxseed oil may reduce reduce the risk of osteoporosis

Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health.

23 Nov 2009

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Researchers are invited to contribute their abstracts to the World Congress on Osteoporosis 2010 (IOF WCO - ECCEO10), the largest global meeting devoted to all aspects of osteoporosis and osteoarthritis research and patient care. The Congress will be held in Florence, Italy from May 5-8, 2010.

21 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

VisEn Medical launches two new agents for imaging quantification

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis.

19 Nov 2009

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

Researchers from the German Sport University Cologne in Germany found that non-steroidal and tissue-selective anabolic agents such as Selective Androgen Receptor Modulators (SARMs) are being sold on the black market for their performance enhancing qualities.

19 Nov 2009

New mathematical model may hasten drug development for Parkinson's Disease

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.

19 Nov 2009

Third-quarter 2009 results announced by Tongjitang Chinese Medicines

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended September 30, 2009 and the repurchase of ordinary shares in a private transaction.

18 Nov 2009

Osteoporosis News and Research

Latest Osteoporosis News and Research

Scientists attribute breast cancer decline to publicity surrounding WHI results

New approach to protein misfolding may lead to novel therapies for a number of diseases

Patients new to chronic disease medication face risk of medication discontinuation, finds study

Orthofix International announces the launch of its FUSION Lateral OA Brace

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Osseon Therapeutics' Osseoflex and Osseoflex DR systems receive Canadian Medical Device Licenses

Lung disease linked to the use of contaminated well water in a CPAP machine

New preventive screening packages for heart disease

Anti-Aging Institute of California offers 'Don't Pause' to get rid of menopause symptoms

OSEO awards fund for Galapagos NV's antibody therapeutics program

Scientists offer first genetic proof of new and rational treatment for osteoporosis

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Flaxseed oil may reduce reduce the risk of osteoporosis

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

VisEn Medical launches two new agents for imaging quantification

Findings suggest athletes abuse non-approved therapeutic compounds for performance enhancing effects

New mathematical model may hasten drug development for Parkinson's Disease

Third-quarter 2009 results announced by Tongjitang Chinese Medicines

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Osteoporosis News and Research

Latest Osteoporosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in